MedTrace Logo

TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program

NCT00569751 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5016

Last updated 2008-09-29

No results posted yet for this study

Summary

The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUSâ„¢ Express2â„¢ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.

Conditions

Interventions

DEVICE

TAXUSâ„¢ Express2â„¢ Paclitaxel-Eluting Coronary Stent System

Drug Eluting Stent used to treat de novo coronary artery lesions.

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Eileen Rose, MS · Boston Scientific Corporation

  • John M Lasala, MD, PhD · Washington University School of Medicine

  • David A. Cox, MD · Lehigh Valley Physician Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2006-11-30
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00569751 on ClinicalTrials.gov